Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis

Class:IdLiteratureReference:9708750
_displayNameTeriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis
_timestamp2020-12-01 11:54:34
author[Person:9708784] Palmer, Alan M
created[InstanceEdit:9708748] Jassal, Bijay, 2020-12-01
journalCurr Opin Investig Drugs
pages1313-23
pubMedIdentifier21157651
titleTeriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis
volume11
year2010
(literatureReference)[Reaction:9708759] DHODH:FMN binds DHODH inhibitors [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis (9708750)